Norman Sitali

5 ta ish

MSF, Berlin, Germany

1. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

   Parvati Nair, T. Hasan, K. K. Zaw +9

   MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20223 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.281624

2. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

   S. Moe, M. L. Rekart, D. Hernandez +9

   MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20231 iqtibos

   ABIABI:AkademIndex/openalex/2026.other.281628

3. Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

   S. Moe, I. Azamat, Sholpan Allamuratova +14

   MaqolaTuberculosis Research and EpidemiologyIJTLD OPEN20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.001030

4. A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

   Michael L. Rekart, Phone Thit, Modupe Oluya +14

   Sharh maqolaTuberculosis Research and EpidemiologyIJTLD OPEN20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.review-article.000146

5. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   MaqolaTuberculosis Research and EpidemiologyClinical Infectious Diseases20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000230